



FIG. 1




Effect of prophylactic administration of human-type lactoferrin on accumulation of albumin by intraperitoneal administration of LPS

FIG. 2




Study of influence of LPS on the blood neutrophil number and the effect of human-type lactoferrin on the suppression of excessive increase of neutrophil number

FIG. 3



Comparison of the effect of human-type lactoferrin(hLF) and bovine-type lactoferrin(bLF) on the albumin concentration in lavage-fluid of the abdominal cavity detected under LPS induction; hLF: SIGMA Chemical Co.; bLF:Wako Pure Chemical Ind.


FIG. 4



The effect of human-type lactoferrin(hLF) and bovine-type lactoferrin (bLF) on the TNF α concentration in the plasma detected under LPS induction

hLF:SIGMA Chemical Co.; bLF:Wako Pure Chemical Ind.


FIG. 5



Effect of human-type lactoferrin on accumulation of ascites
under LPS-induced inflammation


hLF:SIGMA Chemical Co.

FIG. 6



Effect of human-type lactoferrin on albumin accumulation in the abdominal cavity
under LPS induction: Difference in the time of lactoferrin administration
(- before administration time + after administration time)

FIG. 7



Difference of the route of human-type lactoferrin administration influenced on decrease of albumin accumulation under LPS-induced inflammation